Healthcare >> CEO Interviews >> November 1, 2002
MICHAEL S. OSTRACH is President and Chief Operating Officer of
Kosan Biosciences Inc. Prior to joining Kosan in October 1997,
Mr. Ostrach was Chief Operating Officer of Neurobiological
Technologies, Inc.; President of Chiron Technologies, a business
unit of Chiron Corporation; and Senior Vice President, Corporate
Affairs and General Counsel of Cetus Corporation. Mr. Ostrach
holds a BA from Brown University and a JD from Stanford Law
School. Dr. Robert Johnson is Senior Vice President, Medical
Affairs and Corporate Development of Kosan Biosciences Inc. Prior
to joining Kosan in September 2000, Dr. Johnson was employed by
Chiron Corporation from 1998, serving as Vice President,
Corporate Pharmacology and Preclinical Affairs through 1999 and
most recently as Vice President, Corporate Development. From 1991
to 1998, Dr. Johnson was Director of Pharmacology at Merck & Co.,
Inc. In addition, Dr. Johnson was a member of the faculty at the
University of Pennsylvania from 1987 to 1991 and at Harvard
Medical School from 1985 to 1987. Dr. Johnson received his BA and
PhD in Biophysics and his MD from the University of Pennsylvania. Profile
on over the past year that investors should focus on?
Mr. Ostrach: The most significant point for investors is that
Kosan
